| Pair Name | Luteolin, Sorafenib | ||
| Phytochemical Name | Luteolin (PubChem CID: 5280445 ) | ||
| Anticancer drug Name | Sorafenib (PubChem CID: 216239 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Luteolin, Sorafenib | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Cleavage | CASP3 | hsa836 |
| Up-regulation | Phosphorylation | MAPK8 | hsa5599 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| In Vitro Model | Hep 3B2.1-7 | Childhood hepatocellular carcinoma | Homo sapiens (Human) | CVCL_0326 |
| SMMC-7721 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0534 | |
| Result | Sorafenib and luteolin combination synergistically kills HCC cells through JNK-mediated apoptosis, and luteolin may be an ideal candidate for increasing the activity of sorafenib in HCC therapy. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Luteolin and sorafenib combination kills human hepatocellular carcinoma cells through apoptosis potentiation and JNK activation. Oncol Lett. 2018 Jul;16(1):648-653. doi: 10.3892/ol.2018.8640. | Click |
